Helix BioPharma Corp.
Helix BioPharma Corp. (HBP.TO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
hbp.to · pe ratio · data through Jul 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Helix BioPharma Corp. (HBP.TO) measures how much investors pay for each dollar of the company's trailing earnings. HBP.TO's current PE ratio of N/A is calculated by dividing its stock price of $1.53 by its TTM earnings per share of -$0.05.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-07-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Helix BioPharma Corp.You HBP.TO | $117M | N/A | — | -$0.05 |
 Cardiol Therapeutics Inc. CRDL.TO | $169M | N/A | — | -$0.39 |
 Cybin Inc. CYBN.NE | $136M | N/A | — | -$0.61 |
 HLS Therapeutics Inc. HLS.TO | $138M | N/A | — | -$0.40 |
 Jushi Holdings Inc. JUSH.CN | $148M | N/A | — | -$0.35 |
 Cannara Biotech Inc. LOVE.V | $181M | 12.86x | — | $0.14 |
 Medicenna Therapeutics Corp. MDNA.TO | $30M | N/A | — | -$0.15 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-07-31Latest FY2025 | — | $-0.09 | — | |
2024-07-31 FY2024 | — | $-0.21 | — | |
2023-07-31 FY2023 | — | $-0.16 | — | |
2022-07-31 FY2022 | — | $-0.20 | — | |
2021-07-31 FY2021 | — | $-0.29 | — | |
2020-07-31 FY2020 | — | $-0.35 | — | |
2019-07-31 FY2019 | — | $-0.35 | — | |
2018-07-31 FY2018 | — | $-0.43 | — | |
2017-07-31 FY2017 | — | $-0.55 | — | |
2016-07-31 FY2016 | — | $-0.57 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Helix BioPharma Corp. (HBP.TO) measures how much investors pay for each dollar of the company's trailing earnings. HBP.TO's current PE ratio of N/A is calculated by dividing its stock price of $1.53 by its TTM earnings per share of -$0.05.
Frequently asked questions
HBP.TO pe ratio · 6 questionsHBP.TO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $1.53 and TTM EPS of -$0.05. Data sourced from Financial Modeling Prep via HBP.TO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Helix BioPharma Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08